Why participate?<\/h1><\/div><\/div><\/div><\/div><\/div>When you participate in E\u00b2-RADIatE, you will be given several rights and privileges.<\/p>\n<\/div>
<\/div><\/div><\/div>![\"Authorship](\"https:\/\/project.eortc.org\/e2-radiate\/wp-content\/uploads\/sites\/11\/2019\/11\/authorship.png\")
<\/div>Authorship<\/h4><\/a><\/div><\/div><\/div>![\"Benchmarking](\"https:\/\/project.eortc.org\/e2-radiate\/wp-content\/uploads\/sites\/11\/2019\/11\/benchmarking-reports.png\")
<\/div>Benchmarking reports<\/h4><\/a><\/div><\/div><\/div>![\"Clinical](\"https:\/\/project.eortc.org\/e2-radiate\/wp-content\/uploads\/sites\/11\/2019\/11\/clinical-decision-making.png\")
<\/div>Clinical decision making<\/h4><\/a><\/div><\/div><\/div>![\"Data](\"https:\/\/project.eortc.org\/e2-radiate\/wp-content\/uploads\/sites\/11\/2019\/11\/data-sharing.png\")
<\/div>Priority access to data sharing<\/h4><\/a><\/div><\/div><\/div>![\"Networking](\"https:\/\/project.eortc.org\/e2-radiate\/wp-content\/uploads\/sites\/11\/2019\/11\/Networking.png\")
<\/div>Networking<\/h4><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Authorship<\/h3><\/div>Participating investigators will have the opportunity to be represented in publications, based on certain authorship rules described for E\u00b2-RADIatE and relevant cohorts.
\nThis will follow the principle of maximum inclusivity.<\/p>\n
The authorship rules are in line with EORTC publication policies and conform to the recommendations of the International Committee of Medical Journal Editors defining the roles of authors and contributors.<\/p>\n
The authorship rules are described hereunder:<\/p>\n
\n- The Project lead Principal Investigator is the first author, unless he\/she has included no patient. The PI is usually the person who conceived the project, unless otherwise agreed and, consequently, he\/she is expected to be the first author. However, the E\u00b2-RADIatE Steering Committee has the final say to define and decide on first authorship, should a dispute arise.<\/li>\n
- The Cohort Coordinating Committee of a cohort will decide their authorship rule based contribution.<\/li>\n
- Participating investigators will be represented on the publication as defined by the Coordinating Committee of the cohort, following the principle of maximum inclusivity of contributors.<\/li>\n
- Should authorship be limited in space, the Cohort Coordinating Committee of the cohort will decide at their best<\/li>\n
- Non-clinical authors will be appointed as needed. At minimum, the study statistician and those from the coordination office who substantially contributed must be co-authors.<\/li>\n
- All publications are made on behalf of the founding bodies (ESTRO and EORTC) and E\u00b2-RADIatE.<\/li>\n
- Contributors (individuals who could not be listed as authors) and other partners or stakeholders should be both acknowledged and made clearly visible in the main publication.<\/li>\n
- Related publications (secondary analysis, etc.) should recognize fair authorship representation of all contributors. Decisions should be discussed at the level of the Steering Committee. In case of emerging conflicts, the E\u00b2-RADIatE Steering Committee has the responsibility to take and enforce a fair and neutral decision.<\/li>\n<\/ul>\n
For Cohorts<\/strong>, the following rules will also apply:<\/p>\nFirst author: Principle Investigator (PI) of a sub-project
\nLast author: Not pre-defined
\nCo-authors: as inclusive as possible, but with a dynamic, 2-stepped approach:<\/p>\n
\n- Members of the OligoCare Study group\/Consortium are listed on general OligoCare publications. This includes all members of the Coordinating Committee for OligoCare, all members of the three OligoCare Work Packages, and all institutional PIs who enrolled patients (min. 3 patients per year and with complete data set).<\/li>\n
- Other authors will be included on a publication related to a specific research question, when the data of patients included by the institution are used for answering that research question.<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
Benchmarking on outcomes<\/h3><\/div>Participating centres may request benchmarking reports that rank their institution against other (de-identified) institutions. The content will depend on the cohort, but minimally, the treatment characteristics and patient outcomes can be included.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Clinical decision making<\/h3><\/div>Contributors have a role in helping to make clinical decisions. When the platform contains data from a large number of patients, it will be possible to identify patient subgroups. Analysing outcomes based on treatments for these subgroups can contribute in providing more personalized medicine. This will help the clinician make the right treatment choice for their patient. If clinical decision support tools are developed, these can be made available to data contributors.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Priority access to data sharing<\/h3><\/div>We are committed to ensuring that the data generated from this study is put to good use by the cancer research community and, whenever possible, translated to delivering patient benefits. Request for data access by qualified scientific and medical researchers will be possible whilst safeguarding intellectual property, the privacy of patients and confidentiality.
\nParticipating investigators will have priority when requesting data for a scientific project.<\/p>\n<\/div>
When you participate in E\u00b2-RADIatE, you will be given several rights and privileges.<\/p>\n<\/div>
<\/div>Authorship<\/h4><\/a><\/div><\/div><\/div><\/div>Benchmarking reports<\/h4><\/a><\/div><\/div><\/div><\/div>Clinical decision making<\/h4><\/a><\/div><\/div><\/div><\/div>Priority access to data sharing<\/h4><\/a><\/div><\/div><\/div><\/div>Networking<\/h4><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Authorship<\/h3><\/div>Participating investigators will have the opportunity to be represented in publications, based on certain authorship rules described for E\u00b2-RADIatE and relevant cohorts.
\nThis will follow the principle of maximum inclusivity.<\/p>\n
The authorship rules are in line with EORTC publication policies and conform to the recommendations of the International Committee of Medical Journal Editors defining the roles of authors and contributors.<\/p>\n
The authorship rules are described hereunder:<\/p>\n
\n- The Project lead Principal Investigator is the first author, unless he\/she has included no patient. The PI is usually the person who conceived the project, unless otherwise agreed and, consequently, he\/she is expected to be the first author. However, the E\u00b2-RADIatE Steering Committee has the final say to define and decide on first authorship, should a dispute arise.<\/li>\n
- The Cohort Coordinating Committee of a cohort will decide their authorship rule based contribution.<\/li>\n
- Participating investigators will be represented on the publication as defined by the Coordinating Committee of the cohort, following the principle of maximum inclusivity of contributors.<\/li>\n
- Should authorship be limited in space, the Cohort Coordinating Committee of the cohort will decide at their best<\/li>\n
- Non-clinical authors will be appointed as needed. At minimum, the study statistician and those from the coordination office who substantially contributed must be co-authors.<\/li>\n
- All publications are made on behalf of the founding bodies (ESTRO and EORTC) and E\u00b2-RADIatE.<\/li>\n
- Contributors (individuals who could not be listed as authors) and other partners or stakeholders should be both acknowledged and made clearly visible in the main publication.<\/li>\n
- Related publications (secondary analysis, etc.) should recognize fair authorship representation of all contributors. Decisions should be discussed at the level of the Steering Committee. In case of emerging conflicts, the E\u00b2-RADIatE Steering Committee has the responsibility to take and enforce a fair and neutral decision.<\/li>\n<\/ul>\n
For Cohorts<\/strong>, the following rules will also apply:<\/p>\nFirst author: Principle Investigator (PI) of a sub-project
\nLast author: Not pre-defined
\nCo-authors: as inclusive as possible, but with a dynamic, 2-stepped approach:<\/p>\n
\n- Members of the OligoCare Study group\/Consortium are listed on general OligoCare publications. This includes all members of the Coordinating Committee for OligoCare, all members of the three OligoCare Work Packages, and all institutional PIs who enrolled patients (min. 3 patients per year and with complete data set).<\/li>\n
- Other authors will be included on a publication related to a specific research question, when the data of patients included by the institution are used for answering that research question.<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
Benchmarking on outcomes<\/h3><\/div>Participating centres may request benchmarking reports that rank their institution against other (de-identified) institutions. The content will depend on the cohort, but minimally, the treatment characteristics and patient outcomes can be included.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Clinical decision making<\/h3><\/div>Contributors have a role in helping to make clinical decisions. When the platform contains data from a large number of patients, it will be possible to identify patient subgroups. Analysing outcomes based on treatments for these subgroups can contribute in providing more personalized medicine. This will help the clinician make the right treatment choice for their patient. If clinical decision support tools are developed, these can be made available to data contributors.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Priority access to data sharing<\/h3><\/div>We are committed to ensuring that the data generated from this study is put to good use by the cancer research community and, whenever possible, translated to delivering patient benefits. Request for data access by qualified scientific and medical researchers will be possible whilst safeguarding intellectual property, the privacy of patients and confidentiality.
\nParticipating investigators will have priority when requesting data for a scientific project.<\/p>\n<\/div>
<\/div>Benchmarking reports<\/h4><\/a><\/div><\/div><\/div><\/div>Clinical decision making<\/h4><\/a><\/div><\/div><\/div><\/div>Priority access to data sharing<\/h4><\/a><\/div><\/div><\/div><\/div>Networking<\/h4><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Authorship<\/h3><\/div>Participating investigators will have the opportunity to be represented in publications, based on certain authorship rules described for E\u00b2-RADIatE and relevant cohorts.
\nThis will follow the principle of maximum inclusivity.<\/p>\n
The authorship rules are in line with EORTC publication policies and conform to the recommendations of the International Committee of Medical Journal Editors defining the roles of authors and contributors.<\/p>\n
The authorship rules are described hereunder:<\/p>\n
\n- The Project lead Principal Investigator is the first author, unless he\/she has included no patient. The PI is usually the person who conceived the project, unless otherwise agreed and, consequently, he\/she is expected to be the first author. However, the E\u00b2-RADIatE Steering Committee has the final say to define and decide on first authorship, should a dispute arise.<\/li>\n
- The Cohort Coordinating Committee of a cohort will decide their authorship rule based contribution.<\/li>\n
- Participating investigators will be represented on the publication as defined by the Coordinating Committee of the cohort, following the principle of maximum inclusivity of contributors.<\/li>\n
- Should authorship be limited in space, the Cohort Coordinating Committee of the cohort will decide at their best<\/li>\n
- Non-clinical authors will be appointed as needed. At minimum, the study statistician and those from the coordination office who substantially contributed must be co-authors.<\/li>\n
- All publications are made on behalf of the founding bodies (ESTRO and EORTC) and E\u00b2-RADIatE.<\/li>\n
- Contributors (individuals who could not be listed as authors) and other partners or stakeholders should be both acknowledged and made clearly visible in the main publication.<\/li>\n
- Related publications (secondary analysis, etc.) should recognize fair authorship representation of all contributors. Decisions should be discussed at the level of the Steering Committee. In case of emerging conflicts, the E\u00b2-RADIatE Steering Committee has the responsibility to take and enforce a fair and neutral decision.<\/li>\n<\/ul>\n
For Cohorts<\/strong>, the following rules will also apply:<\/p>\nFirst author: Principle Investigator (PI) of a sub-project
\nLast author: Not pre-defined
\nCo-authors: as inclusive as possible, but with a dynamic, 2-stepped approach:<\/p>\n
\n- Members of the OligoCare Study group\/Consortium are listed on general OligoCare publications. This includes all members of the Coordinating Committee for OligoCare, all members of the three OligoCare Work Packages, and all institutional PIs who enrolled patients (min. 3 patients per year and with complete data set).<\/li>\n
- Other authors will be included on a publication related to a specific research question, when the data of patients included by the institution are used for answering that research question.<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
Benchmarking on outcomes<\/h3><\/div>Participating centres may request benchmarking reports that rank their institution against other (de-identified) institutions. The content will depend on the cohort, but minimally, the treatment characteristics and patient outcomes can be included.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Clinical decision making<\/h3><\/div>Contributors have a role in helping to make clinical decisions. When the platform contains data from a large number of patients, it will be possible to identify patient subgroups. Analysing outcomes based on treatments for these subgroups can contribute in providing more personalized medicine. This will help the clinician make the right treatment choice for their patient. If clinical decision support tools are developed, these can be made available to data contributors.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Priority access to data sharing<\/h3><\/div>We are committed to ensuring that the data generated from this study is put to good use by the cancer research community and, whenever possible, translated to delivering patient benefits. Request for data access by qualified scientific and medical researchers will be possible whilst safeguarding intellectual property, the privacy of patients and confidentiality.
\nParticipating investigators will have priority when requesting data for a scientific project.<\/p>\n<\/div>
<\/div>Clinical decision making<\/h4><\/a><\/div><\/div><\/div><\/div>Priority access to data sharing<\/h4><\/a><\/div><\/div><\/div><\/div>Networking<\/h4><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Authorship<\/h3><\/div>Participating investigators will have the opportunity to be represented in publications, based on certain authorship rules described for E\u00b2-RADIatE and relevant cohorts.
\nThis will follow the principle of maximum inclusivity.<\/p>\n
The authorship rules are in line with EORTC publication policies and conform to the recommendations of the International Committee of Medical Journal Editors defining the roles of authors and contributors.<\/p>\n
The authorship rules are described hereunder:<\/p>\n
\n- The Project lead Principal Investigator is the first author, unless he\/she has included no patient. The PI is usually the person who conceived the project, unless otherwise agreed and, consequently, he\/she is expected to be the first author. However, the E\u00b2-RADIatE Steering Committee has the final say to define and decide on first authorship, should a dispute arise.<\/li>\n
- The Cohort Coordinating Committee of a cohort will decide their authorship rule based contribution.<\/li>\n
- Participating investigators will be represented on the publication as defined by the Coordinating Committee of the cohort, following the principle of maximum inclusivity of contributors.<\/li>\n
- Should authorship be limited in space, the Cohort Coordinating Committee of the cohort will decide at their best<\/li>\n
- Non-clinical authors will be appointed as needed. At minimum, the study statistician and those from the coordination office who substantially contributed must be co-authors.<\/li>\n
- All publications are made on behalf of the founding bodies (ESTRO and EORTC) and E\u00b2-RADIatE.<\/li>\n
- Contributors (individuals who could not be listed as authors) and other partners or stakeholders should be both acknowledged and made clearly visible in the main publication.<\/li>\n
- Related publications (secondary analysis, etc.) should recognize fair authorship representation of all contributors. Decisions should be discussed at the level of the Steering Committee. In case of emerging conflicts, the E\u00b2-RADIatE Steering Committee has the responsibility to take and enforce a fair and neutral decision.<\/li>\n<\/ul>\n
For Cohorts<\/strong>, the following rules will also apply:<\/p>\nFirst author: Principle Investigator (PI) of a sub-project
\nLast author: Not pre-defined
\nCo-authors: as inclusive as possible, but with a dynamic, 2-stepped approach:<\/p>\n
\n- Members of the OligoCare Study group\/Consortium are listed on general OligoCare publications. This includes all members of the Coordinating Committee for OligoCare, all members of the three OligoCare Work Packages, and all institutional PIs who enrolled patients (min. 3 patients per year and with complete data set).<\/li>\n
- Other authors will be included on a publication related to a specific research question, when the data of patients included by the institution are used for answering that research question.<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
Benchmarking on outcomes<\/h3><\/div>Participating centres may request benchmarking reports that rank their institution against other (de-identified) institutions. The content will depend on the cohort, but minimally, the treatment characteristics and patient outcomes can be included.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Clinical decision making<\/h3><\/div>Contributors have a role in helping to make clinical decisions. When the platform contains data from a large number of patients, it will be possible to identify patient subgroups. Analysing outcomes based on treatments for these subgroups can contribute in providing more personalized medicine. This will help the clinician make the right treatment choice for their patient. If clinical decision support tools are developed, these can be made available to data contributors.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Priority access to data sharing<\/h3><\/div>We are committed to ensuring that the data generated from this study is put to good use by the cancer research community and, whenever possible, translated to delivering patient benefits. Request for data access by qualified scientific and medical researchers will be possible whilst safeguarding intellectual property, the privacy of patients and confidentiality.
\nParticipating investigators will have priority when requesting data for a scientific project.<\/p>\n<\/div>
<\/div>Priority access to data sharing<\/h4><\/a><\/div><\/div><\/div><\/div>Networking<\/h4><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Authorship<\/h3><\/div>Participating investigators will have the opportunity to be represented in publications, based on certain authorship rules described for E\u00b2-RADIatE and relevant cohorts.
\nThis will follow the principle of maximum inclusivity.<\/p>\n
The authorship rules are in line with EORTC publication policies and conform to the recommendations of the International Committee of Medical Journal Editors defining the roles of authors and contributors.<\/p>\n
The authorship rules are described hereunder:<\/p>\n
\n- The Project lead Principal Investigator is the first author, unless he\/she has included no patient. The PI is usually the person who conceived the project, unless otherwise agreed and, consequently, he\/she is expected to be the first author. However, the E\u00b2-RADIatE Steering Committee has the final say to define and decide on first authorship, should a dispute arise.<\/li>\n
- The Cohort Coordinating Committee of a cohort will decide their authorship rule based contribution.<\/li>\n
- Participating investigators will be represented on the publication as defined by the Coordinating Committee of the cohort, following the principle of maximum inclusivity of contributors.<\/li>\n
- Should authorship be limited in space, the Cohort Coordinating Committee of the cohort will decide at their best<\/li>\n
- Non-clinical authors will be appointed as needed. At minimum, the study statistician and those from the coordination office who substantially contributed must be co-authors.<\/li>\n
- All publications are made on behalf of the founding bodies (ESTRO and EORTC) and E\u00b2-RADIatE.<\/li>\n
- Contributors (individuals who could not be listed as authors) and other partners or stakeholders should be both acknowledged and made clearly visible in the main publication.<\/li>\n
- Related publications (secondary analysis, etc.) should recognize fair authorship representation of all contributors. Decisions should be discussed at the level of the Steering Committee. In case of emerging conflicts, the E\u00b2-RADIatE Steering Committee has the responsibility to take and enforce a fair and neutral decision.<\/li>\n<\/ul>\n
For Cohorts<\/strong>, the following rules will also apply:<\/p>\nFirst author: Principle Investigator (PI) of a sub-project
\nLast author: Not pre-defined
\nCo-authors: as inclusive as possible, but with a dynamic, 2-stepped approach:<\/p>\n
\n- Members of the OligoCare Study group\/Consortium are listed on general OligoCare publications. This includes all members of the Coordinating Committee for OligoCare, all members of the three OligoCare Work Packages, and all institutional PIs who enrolled patients (min. 3 patients per year and with complete data set).<\/li>\n
- Other authors will be included on a publication related to a specific research question, when the data of patients included by the institution are used for answering that research question.<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
Benchmarking on outcomes<\/h3><\/div>Participating centres may request benchmarking reports that rank their institution against other (de-identified) institutions. The content will depend on the cohort, but minimally, the treatment characteristics and patient outcomes can be included.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Clinical decision making<\/h3><\/div>Contributors have a role in helping to make clinical decisions. When the platform contains data from a large number of patients, it will be possible to identify patient subgroups. Analysing outcomes based on treatments for these subgroups can contribute in providing more personalized medicine. This will help the clinician make the right treatment choice for their patient. If clinical decision support tools are developed, these can be made available to data contributors.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Priority access to data sharing<\/h3><\/div>We are committed to ensuring that the data generated from this study is put to good use by the cancer research community and, whenever possible, translated to delivering patient benefits. Request for data access by qualified scientific and medical researchers will be possible whilst safeguarding intellectual property, the privacy of patients and confidentiality.
\nParticipating investigators will have priority when requesting data for a scientific project.<\/p>\n<\/div>
<\/div>Networking<\/h4><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Authorship<\/h3><\/div>Participating investigators will have the opportunity to be represented in publications, based on certain authorship rules described for E\u00b2-RADIatE and relevant cohorts.
\nThis will follow the principle of maximum inclusivity.<\/p>\n
The authorship rules are in line with EORTC publication policies and conform to the recommendations of the International Committee of Medical Journal Editors defining the roles of authors and contributors.<\/p>\n
The authorship rules are described hereunder:<\/p>\n
\n- The Project lead Principal Investigator is the first author, unless he\/she has included no patient. The PI is usually the person who conceived the project, unless otherwise agreed and, consequently, he\/she is expected to be the first author. However, the E\u00b2-RADIatE Steering Committee has the final say to define and decide on first authorship, should a dispute arise.<\/li>\n
- The Cohort Coordinating Committee of a cohort will decide their authorship rule based contribution.<\/li>\n
- Participating investigators will be represented on the publication as defined by the Coordinating Committee of the cohort, following the principle of maximum inclusivity of contributors.<\/li>\n
- Should authorship be limited in space, the Cohort Coordinating Committee of the cohort will decide at their best<\/li>\n
- Non-clinical authors will be appointed as needed. At minimum, the study statistician and those from the coordination office who substantially contributed must be co-authors.<\/li>\n
- All publications are made on behalf of the founding bodies (ESTRO and EORTC) and E\u00b2-RADIatE.<\/li>\n
- Contributors (individuals who could not be listed as authors) and other partners or stakeholders should be both acknowledged and made clearly visible in the main publication.<\/li>\n
- Related publications (secondary analysis, etc.) should recognize fair authorship representation of all contributors. Decisions should be discussed at the level of the Steering Committee. In case of emerging conflicts, the E\u00b2-RADIatE Steering Committee has the responsibility to take and enforce a fair and neutral decision.<\/li>\n<\/ul>\n
For Cohorts<\/strong>, the following rules will also apply:<\/p>\nFirst author: Principle Investigator (PI) of a sub-project
\nLast author: Not pre-defined
\nCo-authors: as inclusive as possible, but with a dynamic, 2-stepped approach:<\/p>\n
\n- Members of the OligoCare Study group\/Consortium are listed on general OligoCare publications. This includes all members of the Coordinating Committee for OligoCare, all members of the three OligoCare Work Packages, and all institutional PIs who enrolled patients (min. 3 patients per year and with complete data set).<\/li>\n
- Other authors will be included on a publication related to a specific research question, when the data of patients included by the institution are used for answering that research question.<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
Benchmarking on outcomes<\/h3><\/div>Participating centres may request benchmarking reports that rank their institution against other (de-identified) institutions. The content will depend on the cohort, but minimally, the treatment characteristics and patient outcomes can be included.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Clinical decision making<\/h3><\/div>Contributors have a role in helping to make clinical decisions. When the platform contains data from a large number of patients, it will be possible to identify patient subgroups. Analysing outcomes based on treatments for these subgroups can contribute in providing more personalized medicine. This will help the clinician make the right treatment choice for their patient. If clinical decision support tools are developed, these can be made available to data contributors.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Priority access to data sharing<\/h3><\/div>We are committed to ensuring that the data generated from this study is put to good use by the cancer research community and, whenever possible, translated to delivering patient benefits. Request for data access by qualified scientific and medical researchers will be possible whilst safeguarding intellectual property, the privacy of patients and confidentiality.
\nParticipating investigators will have priority when requesting data for a scientific project.<\/p>\n<\/div>
Authorship<\/h3><\/div>Participating investigators will have the opportunity to be represented in publications, based on certain authorship rules described for E\u00b2-RADIatE and relevant cohorts.
\nThis will follow the principle of maximum inclusivity.<\/p>\n
The authorship rules are in line with EORTC publication policies and conform to the recommendations of the International Committee of Medical Journal Editors defining the roles of authors and contributors.<\/p>\n
The authorship rules are described hereunder:<\/p>\n
\n- The Project lead Principal Investigator is the first author, unless he\/she has included no patient. The PI is usually the person who conceived the project, unless otherwise agreed and, consequently, he\/she is expected to be the first author. However, the E\u00b2-RADIatE Steering Committee has the final say to define and decide on first authorship, should a dispute arise.<\/li>\n
- The Cohort Coordinating Committee of a cohort will decide their authorship rule based contribution.<\/li>\n
- Participating investigators will be represented on the publication as defined by the Coordinating Committee of the cohort, following the principle of maximum inclusivity of contributors.<\/li>\n
- Should authorship be limited in space, the Cohort Coordinating Committee of the cohort will decide at their best<\/li>\n
- Non-clinical authors will be appointed as needed. At minimum, the study statistician and those from the coordination office who substantially contributed must be co-authors.<\/li>\n
- All publications are made on behalf of the founding bodies (ESTRO and EORTC) and E\u00b2-RADIatE.<\/li>\n
- Contributors (individuals who could not be listed as authors) and other partners or stakeholders should be both acknowledged and made clearly visible in the main publication.<\/li>\n
- Related publications (secondary analysis, etc.) should recognize fair authorship representation of all contributors. Decisions should be discussed at the level of the Steering Committee. In case of emerging conflicts, the E\u00b2-RADIatE Steering Committee has the responsibility to take and enforce a fair and neutral decision.<\/li>\n<\/ul>\n
For Cohorts<\/strong>, the following rules will also apply:<\/p>\nFirst author: Principle Investigator (PI) of a sub-project
\nLast author: Not pre-defined
\nCo-authors: as inclusive as possible, but with a dynamic, 2-stepped approach:<\/p>\n
\n- Members of the OligoCare Study group\/Consortium are listed on general OligoCare publications. This includes all members of the Coordinating Committee for OligoCare, all members of the three OligoCare Work Packages, and all institutional PIs who enrolled patients (min. 3 patients per year and with complete data set).<\/li>\n
- Other authors will be included on a publication related to a specific research question, when the data of patients included by the institution are used for answering that research question.<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
Benchmarking on outcomes<\/h3><\/div>Participating centres may request benchmarking reports that rank their institution against other (de-identified) institutions. The content will depend on the cohort, but minimally, the treatment characteristics and patient outcomes can be included.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Clinical decision making<\/h3><\/div>Contributors have a role in helping to make clinical decisions. When the platform contains data from a large number of patients, it will be possible to identify patient subgroups. Analysing outcomes based on treatments for these subgroups can contribute in providing more personalized medicine. This will help the clinician make the right treatment choice for their patient. If clinical decision support tools are developed, these can be made available to data contributors.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Priority access to data sharing<\/h3><\/div>We are committed to ensuring that the data generated from this study is put to good use by the cancer research community and, whenever possible, translated to delivering patient benefits. Request for data access by qualified scientific and medical researchers will be possible whilst safeguarding intellectual property, the privacy of patients and confidentiality.
\nParticipating investigators will have priority when requesting data for a scientific project.<\/p>\n<\/div>
Participating investigators will have the opportunity to be represented in publications, based on certain authorship rules described for E\u00b2-RADIatE and relevant cohorts.
\nThis will follow the principle of maximum inclusivity.<\/p>\n
The authorship rules are in line with EORTC publication policies and conform to the recommendations of the International Committee of Medical Journal Editors defining the roles of authors and contributors.<\/p>\n
The authorship rules are described hereunder:<\/p>\n
- \n
- The Project lead Principal Investigator is the first author, unless he\/she has included no patient. The PI is usually the person who conceived the project, unless otherwise agreed and, consequently, he\/she is expected to be the first author. However, the E\u00b2-RADIatE Steering Committee has the final say to define and decide on first authorship, should a dispute arise.<\/li>\n
- The Cohort Coordinating Committee of a cohort will decide their authorship rule based contribution.<\/li>\n
- Participating investigators will be represented on the publication as defined by the Coordinating Committee of the cohort, following the principle of maximum inclusivity of contributors.<\/li>\n
- Should authorship be limited in space, the Cohort Coordinating Committee of the cohort will decide at their best<\/li>\n
- Non-clinical authors will be appointed as needed. At minimum, the study statistician and those from the coordination office who substantially contributed must be co-authors.<\/li>\n
- All publications are made on behalf of the founding bodies (ESTRO and EORTC) and E\u00b2-RADIatE.<\/li>\n
- Contributors (individuals who could not be listed as authors) and other partners or stakeholders should be both acknowledged and made clearly visible in the main publication.<\/li>\n
- Related publications (secondary analysis, etc.) should recognize fair authorship representation of all contributors. Decisions should be discussed at the level of the Steering Committee. In case of emerging conflicts, the E\u00b2-RADIatE Steering Committee has the responsibility to take and enforce a fair and neutral decision.<\/li>\n<\/ul>\n
For Cohorts<\/strong>, the following rules will also apply:<\/p>\n
First author: Principle Investigator (PI) of a sub-project
\nLast author: Not pre-defined
\nCo-authors: as inclusive as possible, but with a dynamic, 2-stepped approach:<\/p>\n- \n
- Members of the OligoCare Study group\/Consortium are listed on general OligoCare publications. This includes all members of the Coordinating Committee for OligoCare, all members of the three OligoCare Work Packages, and all institutional PIs who enrolled patients (min. 3 patients per year and with complete data set).<\/li>\n
- Other authors will be included on a publication related to a specific research question, when the data of patients included by the institution are used for answering that research question.<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
Benchmarking on outcomes<\/h3><\/div>
Participating centres may request benchmarking reports that rank their institution against other (de-identified) institutions. The content will depend on the cohort, but minimally, the treatment characteristics and patient outcomes can be included.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Clinical decision making<\/h3><\/div>
Contributors have a role in helping to make clinical decisions. When the platform contains data from a large number of patients, it will be possible to identify patient subgroups. Analysing outcomes based on treatments for these subgroups can contribute in providing more personalized medicine. This will help the clinician make the right treatment choice for their patient. If clinical decision support tools are developed, these can be made available to data contributors.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div>Priority access to data sharing<\/h3><\/div>
We are committed to ensuring that the data generated from this study is put to good use by the cancer research community and, whenever possible, translated to delivering patient benefits. Request for data access by qualified scientific and medical researchers will be possible whilst safeguarding intellectual property, the privacy of patients and confidentiality.
\nParticipating investigators will have priority when requesting data for a scientific project.<\/p>\n<\/div>